GBM in Disease
The GBM is positioned between the endothelial and epithelial cell layers of the glomerular capillary wall ( Figure 1 ). It is a specialized form of extracellular matrix of~300 to 350 nm in thickness that provides mechanical support, and its components serve as ligands for receptors that influence cell behavior. Another key role of the GBM is ultrafiltration of circulating blood, blocking the passage of cellular components and large proteins from entering the urinary space.
The GBM is affected in several renal diseases ( Figure 1 ). The thickness of the GBM increases in patients with diabetic nephropathy, which together with expansion of the mesangium leads to progressive loss of glomerular filtration (2) . Autoantibodies bind the GBM in patients with GP syndrome, which ignites an overwhelming inflammatory response that leads to the rapid loss of kidney function (3) (4) (5) (6) (7) . Genetic mutations in Alport syndrome cause splitting and multi-laminations of the GBM, which leads to a slow progressive loss of renal function (8 -13) . Also, mutations underlie thin basement membrane disease, leading to hematuria (14 -17) . The commonality of abnormal GBM in these and several other glomerular diseases, as defined by numerous clinical investigations in the 1960s, focused the attention of my research group and other scientists on a quest to define the molecular structure of the GBM as a foundation for unraveling the molecular basis of these diseases.
Importantly, these clinical observations framed fundamental questions about the disease mechanisms. Among them were two simple and direct questions: (1) "What is the identity of the autoantigen of GBM in GP syndrome?" (2) "Which component of the GBM is mutated in Alport syndrome?" In answering these questions, a critical observation was made by several investigators in the early 1980s linking these two syndromes (18 -21) . In a classic paper, Curtis Wilson and colleagues (19) showed that plasma of patients with GP syndrome contained anti-GBM antibodies that would bind the GBM of normal kidney but did not react with the GBM of an Alport kidney ( Figure 2 ). Moreover, anti-GBM antibodies that had developed in a renal transplant recipient with Alport syndrome reacted with the GBM of normal kidneys but not with the GBM of Alport kidney. This led them to conclude that the absent Correspondence to Dr. Billy G. Hudson, Departments of Medicine and Biochemistry, Vanderbilt University School of Medicine, B-3102 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2372. Phone: 615-322-7298; Fax: 615-322-7381; E-mail: billy.hudson@vanderbilt.edu antigen in Alport syndrome is related to the nephritogenic antigen in GP syndrome. The concept of a "molecular commonality" between the two syndromes ultimately served as an intellectual cornerstone for the discovery of collagen IV as a family of six ␣-chains.
Discovery of Collagen IV and the ␣1 and ␣2 Chains
In the mid-1960s and early 70s, studies were focused on the isolation and biochemical characterization of GBM from a variety of animal species (22-29). The findings revealed that the amino acid composition of isolated GBM reflected relatedness with collagen, having a high content of glycine, hydroxyproline, and hydroxylysine. In 1966, Nicolas Kefalides (22) reported the first evidence for the existence of a collagen component in canine GBM, which he designated as collagen IV in a review article in 1973 (30). In the same year, Robert Spiro proposed that the GBM contains collagen-like polypeptides interrupted by noncollagenous sequences (31), a feature later confirmed by protein sequence analysis (32) and molecular cloning (33-36). Many investigators turned to basement membranes of other tissues and animal species to explore the nature of this collagen.
A soluble form of collagen IV was isolated by Rupert Timpl and co-workers (37) from the Engelbreth-Holm-Swarm tumor matrix from mouse tissue and shown to be a triple-helical protomer ( Figure 3) . The protomers were shown to self-assemble through end-to-end associations at their N-terminal (7S domain) to form tetramers and through their C-terminal noncollagenous domain (NC1) to form dimers (37,38). Later, the complete amino acid sequences of the constituent ␣1 and ␣2 chains (mouse and human) were determined by molecular cloning (33-36). We found this collagen also exists in the invertebrate Ascaris suum (39,40). Other investigators found the genes encoding these chains in Drosophila, C. elegans, and Hydra vulgaris (41-44), revealing Ͼ500 million years of evolutionary conservation of their structural features for selfassociation and network formation.
Recent advances in x-ray crystallography allowed us and others to answer a fundamental question about the network structure of the ␣1 and ␣2 chains: "What is the three-dimensional structure of the NC1 hexamer that connects protomers in the network?" (45,46). The x-ray structure of the ␣1.␣2 hexamer has provided molecular insights into the structural basis of protomer and network assembly. In brief, it reveals the detailed interactions of all 20,300 atoms of the NC1 hexamer in which the NC1 monomers have a novel fold of ␤-sheets interacting through a domain-swapping mechanism. As described below, these features provide insights into the pathogenic mechanisms underlying both GP and Alport syndromes (45-47).
Discovery of the ␣3 and ␣4 Chains and Identity of GP Autoantigen
As progress was being made by others on deciphering the molecular structure of collagen IV from the Engelbreth-Holm- Figure 2 . Discovery of a "molecular commonality" in the GBM of patients with Alport and GP syndromes. Autoantibodies from patients with GP syndrome react with the GBM of a normal kidney but fail to react with the GBM of an Alport kidney. Also, anti-GBM alloantibodies, that had developed in a patient with Alport syndrome after receiving a renal allograft, reacted with the GBM of normal kidney but not with the GBM of Alport kidney. These findings indicated the lack of the GP autoantigen in the Alport kidney. Figure 1 . Schematic illustration of human glomerulus in health and disease. Cross-section of a normal human glomerulus shows the three layers of the filtration barrier: the fenestrated endothelium, the glomerular basement membrane (GBM), and the podocyte slit diaphragm (SD) between the podocyte foot processes (FP). The filtration of blood occurs through these three layers with decreasing pore size and increasing selectivity. In thin basement membrane disease, the normal thickness of the GBM is decreased. The GBM in Alport kidney is characterized by irregular thinning and thickening, splitting, and multi-laminations, which lead to progressive renal failure. In Goodpasture (GP) syndrome, the GBM is targeted by autoantibodies, leading to an inflammatory response and loss of filtration function. Thickening of the GBM occurs in diabetic nephropathy, resulting in alteration of the normal structure and function of the GBM.
Swarm tumor matrix, we focused our work to answer the question: "What is the molecular organization of the GBM collagen?" as a strategy to gain insights into GBM abnormalities. We used pepsin (48,49) and chemical extraction (50, 51) to solubilize the components of GBM for biochemical analysis. Later, bacterial collagenase digestion of GBM was used to solubilize the NC1 domains of the known ␣1 and ␣2 chains of collagen IV. Upon excision from the GBM, these NC1 domains appeared as monomers and dimers with molecular masses of~25 and 50 kD (Figure 4) .
In an independent line of inquiry, others (52-57) sought to answer the question, "What is the molecular identity of the GP autoantigen of GBM?" They also used collagenase to digest GBM for solubilization of components, rendering them suitable for biochemical and immunochemical analyses (Figure 4) . Two collagenase-resistant fragments of an~25-kD monomer and an~50-kD dimer were found to react with GP antibodies, but their molecular identities were unknown.
At a Gordon Conference in 1982, we presented our findings about collagen IV, as did Jorgen Wieslander and Per Bygren about GP autoantigen. The two presentations juxtaposed independent findings of two protein fragments, a monomer of 25 kD and a dimer of 50 kD, which in both cases were isolated by collagenase digestion of GBM. It was apparent to both teams that the GP autoantigen was possibly the NC1 domain of the ␣1.␣2 collagen IV network. A collaboration was begun to investigate this hypothesis, which provided evidence that the GP antigen is localized to the NC1 domains of collagen IV (58, 59) . Moreover, these and our other (51) studies established the existence of the ␣1.␣2 network in GBM.
The finding that the GP antigen was the NC1 domain posed another question: "Which chain, ␣1 or ␣2, carries the epitope(s) for GP autoantibodies?" The monomers and dimers from bovine GBM were heterogeneous, existing as a multiplicity of components, designated M1, M2*, and M3 and D1 and D2*. Of these, only M2* and D2* reacted with GP antibodies (60) as did the human M28 3ϩ monomer (61) . To reduce the sample complexity, we investigated the NC1 monomers from lens capsule basement membrane because they displayed a simpler pattern than those of GBM. They were fractionated by chromatography ( Figure 5A ), and then the N-terminal sequences of M1 (a and b), M2*, and M3 were determined by the Edman degradation procedure (62) . To our surprise, the N-terminal sequences of monomers M2*(18 residues) and M3 (17 residues) showed that they were derived from distinct protein species other than ␣1 and ␣2 NC1 monomers, while still having a collagenous origin; i.e., the triplets of Gly-Xaa-Yaa sequences ( Figure 5B ). On the basis of these differences in primary structures and additional differences in physical properties, we proposed that the M2* and M3 monomers were the NC1 domains derived from two novel chains, Figure 3 . Structure of collagen IV protomers and their assembly into networks. The protomer is composed of two ␣1 chains and one ␣2 chain and is characterized by a 7S triple helical domain at the N-terminal containing N-linked carbohydrate moieties, followed by a long triple helical collagenous domain and a noncollagenous NC1 trimer at the C-terminal. Interruptions in the Gly-Xaa-Yaa amino acid sequence at multiple sites along the collagenous domain confer flexibility, allowing for looping and supercoiling of protomers into networks, strengthen with interprotomer disulfide bonds. The protomer is Љsugar coatedЉ in which it contains a N-linked oligosaccharide unit on each chain at the 7S domain, and numerous disaccharide units (not shown) along the full-length collagenous domain (25, 118, 119). Once secreted into the extracellular matrix, collagen IV protomers form networks through dimerization at their C-terminal NC1 domains and through tetramer formation at their N-terminal 7S domains. Figure 4 . Two independent lines of investigation led to the discovery of the ␣3 chain of collagen IV and its identity as the GP autoantigen. One line of investigation was on the chemical characterization of the collagenous component of GBM, and the other line was on the search for the molecular identity of the GP autoantigen. Both lines involved the use of collagenase to solubilize the components that yielded 25-kD monomers and 50-kD dimers. The similarity of these components first led to the identification of the GP antigen as the NC1 domains of the ␣1 and ␣2 chains of collagen IV (58, 59) . Subsequent studies to identify which chain carried the GP epitopes led to the discovery that the epitopes resided in the NC1 domain of a novel chain, designated as the ␣3 chain of collagen IV (62, 64) .
named the ␣3 and ␣4, respectively (62) . The existence of four chains (␣1, ␣2, ␣3, and ␣4) led us to propose the existence of at least two distinct protomers of collagen IV: one composed of the ␣1 and ␣2 chains and the other of the ␣3 and ␣4 chains or a combination of these chains (63) .
The concept of two novel chains was met with controversy. The short N-terminal sequence was considered by some as insufficient information in view of the known primary structure of the ␣1 and ␣2 chains of~1400 residues (33-36). Additional studies by us provided further sequence information that brought the total number of known residues to 32 for the M2* and 30 for M3 (64, 65) . The information provided further evidence that M2* was derived from a novel ␣3 chain and its identity as the GP antigen (62) . The existence of the bovine ␣3 chain was verified 4 yr later by Steve Reeders and co-workers (66) . Using molecular cloning, they isolated a cDNA that contained the 32 residues of the M2* monomer ( Figure 6 ) and that encoded 471 residues of the ␣3 chain. Later, fragments of the human ␣3 chain were cloned (67) (68) (69) , and in 1994, the complete primary structure of the human ␣3 chain was determined (70) (Figure 6 ). Overall, these studies, together with our other study (71) , unambiguously established the existence of the ␣3 chain and its identity as the GP autoantigen. Findings of a partial cDNA sequence encoding the bovine ␣4 chain (72) and a full-length cDNA clone encoding the human ␣4 chain (73) further verified the existence of the ␣4 chain. Figure 6 . The amino acid sequence for the human ␣3 chain of collagen IV. The collagenous domain, characterized by repeat triplet sequence (Gly-Xaa-Yaa) with glycine as every third residue, is distinguished from that of the NC1 domain (red) (70) . The key to the discovery of the ␣3 chain in human was the previous discovery of its corresponding chain in bovine, in which its homologous N-terminal sequence of 32 amino acids residues (shown in the solid box) were derived from bovine M2* monomer and shown to be GLXGKPGDT-GPPAAGAVMRGFVFTRHSQTTAI (62, 64, 65) . These residues were first used to clone the bovine ␣3 chain (66) . The position of GP epitopes on human sequence, E A followed by E B , are indicated (dashed boxes). In an attempt to answer the question, "Which chain, the ␣1 or ␣2, carries the epitope (s) for GP autoantibodies?" the monomers from bovine lens capsule basement membrane were fractionated by HPLC chromatography. The original figure from reference 62 is shown in A. The fractions noted as M1a and b, M2*, and M3 were analyzed by electrophoresis (inset) and by N-terminal amino acid sequence analyses. The sequences of these isolated components were compared (B). M1 and M1b corresponded to the known ␣1 and ␣2 NC1 domains, whereas M2* and M3 were distinctly different. The collagenous origins of the components were indicated by the repeat sequences (Gly-Xaa-Yaa) with glycine as the third residue. The M2* and M3 monomers were designated as NC1 domains derived from novel ␣3 and ␣4 chains of collagen IV and the ␣3 chain as the GP autoantigen (62, 64) .
Discovery of ␣5 and ␣6 Chains and Alport Mutations
The "molecular commonality" between GP and Alport syndromes, defined by earlier studies (Figure 2 ) and confirmed by other studies showing the absence of the 28-kD GP-autoantigen in the Alport GBM (74), provided the conceptual framework for the discovery of two additional chains. On the basis of our discovery of the putative ␣3 chain and its identity as the GP autoantigen, we proposed that protomers and networks that contain the ␣3 chain must be absent in Alport GBM (63); hence, we established the ␣3 chain as the prime candidate for mutations in Alport syndrome. Because the gene locus for Alport had been mapped to position X q22 on the X-chromosome ( Figure 7B ), we hypothesized that the locus for the COL4A3 gene was at the same site ( Figure 7C ) (63) . The defect in Alport syndrome could not be due to the COL4A1 and COL4A2 genes because they had been mapped to chromosome 13 (75, 76) (Figure 7A ).
In 1991, two research groups led by Karl Tryggvason (77) and Jeannie Myers (78) identified cDNA clone encoding a human chain that did not correspond to that of the 34 residues derived from bovine ␣3 chain. At that time, the only sequence available for the ␣3 chain of collagen IV was the 34-residue sequence of the bovine ␣3 chain. With the likelihood of the existence of the ␣3 and ␣4 chains, they designated this new chain as the ␣5 chain of collagen IV and mapped the COL4A5 gene to the Alport locus on the X chromosome ( Figure 7D ) (77, 78) . Mutations in the COL4A5 gene were subsequently discovered in a family with Alport syndrome, confirming the identity of the defective gene (79) . Later, the COL4A3 and COL4A4 genes were identified and mapped to chromosome 2 (80) ( Figure 7E ). The head-to-head orientations of the Figure 7 . Chromosomal localization of the human genes encoding ␣1 to ␣6 chains of collagen IV and the path to discovery of ␣5 and ␣6 chains. (A) The COL4A1 and COL4A2 genes, encoding the ␣1 and ␣2 chains, were the first collagen IV genes to be discovered and their locus mapped to chromosome 13, where they were shown to have a head-to-head orientation. (B) The locus for the Alport gene was mapped to a site on the X-chromosome. (C) The Alport gene was proposed to code for the ␣3 chain on the basis of the "molecular commonality" between GP and Alport syndromes involving the ␣3 chain. (D) Contrary to this proposal, the COL4A5 gene encoding the ␣5 chain was mapped to this site on the X-chromosome, and it was shown to be mutated in patients with Alport syndrome. (E) Later, the COL4A3 and COL4A4 genes encoding the ␣3 and ␣4 chains were mapped to chromosome 2. The head-to-head orientation of the COL4A1 and COL4A2 genes and the COL4A3 and COL4A4 genes posed the question, "Does a COL4A6 gene exist on the X-chromosome to pair with the COL4A5 gene? (F) By positional cloning, the COL4A6 gene encoding the ␣6 chain was discovered.
COL4A1 and COL4A2 genes and the COL4A3 and COL4A4 genes posed the question, "Does a COL4A6 gene exist on the X-chromosome to pair with the COL4A5 gene?" ( Figure 7E ). Indeed, the COL4A6 gene encoding the ␣6 chain of collagen IV was later discovered by two independent groups headed by Steve Reeders and Yoshifumi Ninomiya (81-83). Thus, the six genes are distributed in pairs with a head-to-head organization about three chromosomes ( Figure 7F ). The complete exonintron structure of all six genes in mouse and human revealed a common ancestor gene (84 -90) .
Triple-Helical and Network Organization of the ␣3-␣6 Chains
The discovery that the ␣5 chain is mutated in Alport syndrome posed a key question: "How do mutations in the ␣5 chain cause the absence of the ␣3 chain in Alport GBM?" The answer emerged from our further investigations of the triplehelical and network organization of the collagen IV chains. The well-described organization of the ␣1 and ␣2 chains (Figure 3 ) served as the paradigm for further investigations. The experimental strategies included fragmentation of networks with pseudolysin to release truncated triple-helical molecules (91, 92) and with collagenase (93) to release NC1 hexamers for characterization.
The random combinations of the six ␣-chains theoretically allow for 56 different protomers. Various combinations of protomers could further self-associate, forming a multiplicity of networks that differ with respect to which protomers are connected through end-to-end interactions. However, only three protomers have so far been discovered: the ␣1.␣1.␣2 by others (37) and the ␣3.␣4.␣5 and ␣5.␣5.␣6 by us (Figure 8) (47,94). These protomers form three distinct networks: the ␣1.␣1.␣2 network shown in Figure 3 , the ␣3.␣4.␣5 network shown in Figure 9 , and the ␣1.␣2.␣5.␣6 network (94) (not shown).
Importantly, our discovery of the ␣3.␣4.␣5 network provided a molecular understanding of the linkage between GP syndrome and Alport syndrome that had been established from the clinical studies (Figure 2) (47,92) . Thus, mutations in the ␣5 chain in Alport syndrome could either prevent the assembly of the ␣3.␣4.␣5 protomer or result in defective protomers that cannot self-assemble into a network or are prone to a rapid degradation. Consequently, because the Alport GBM lacks the ␣3.␣4.␣5 network, the GP antigen would be absent as well. The absence of this network in the Alport GBM also explained why sometimes a renal allograft loses its function; in this case, the immune system of the Alport patient recognizes the ␣3.␣4.␣5 network as foreign, which elicits alloantibodies against the ␣3 and ␣5 NC1 domains present in the allograft (95) .
The existence of three networks posed a logical question: "What is the molecular recognition mechanism for assembly of a chain-specific network?" Our studies revealed that the specificity of both protomer and network assembly is governed by "molecular recognition sequences" encoded within the NC1 domains (96) . Thus, the molecular functions of the NC1 domains in assembly are (1) the initial alignment and selection of chains for protomer assembly and (2) the connection and selection of protomers for network assembly. Our recent x-ray structure of the NC1 hexamer provided further insights into this mechanism (45), although the recognition code remains a mystery.
Pathogenesis of GP Syndrome and the Cryptic Epitopes
In 1958, Stanton and Tange (97) described nine patients with a pulmonary-renal disorder that they called Goodpasture syndrome after an earlier report in 1919 by Ernest Goodpasture (98) . The classic presentation of GP syndrome is pulmonary hemorrhage associated with rapidly progressive glomerulonephritis; the syndrome is fatal if left untreated (7). The syndrome is very rare, with an annual incidence of~1 or 2 cases per million in the United States. The landmark studies of Lerner and Dixon (6) revealed that the nephritis is mediated by autoantibodies that bind the GBM.
As described herein, the autoantibodies are now known to target the ␣3.␣4.␣5 network of GBM, as well as alveolar basement membrane (99), and they specifically target the NC1 domain of the ␣3 chain. This knowledge set up a series of key questions about antibody binding: "What is the epitope?" "Where is it located within the primary structure of the NC1 domain?" The major experimental challenge was the conformational nature of the epitope. We resolved this issue by using "gain-of-function" studies with chimeras made of the nonreactive NC1 domain of the ␣1 chain in which unique regions were replaced by the corresponding sequence of ␣3 chain. The findings revealed two conformational epitopes, designated E A and E B , encompassing residues 17 to 31 and 127 to 141 of the ␣3 NC1 domain ( Figure 6 ) (100). Key residues of the E A epitope have been identified by mutation analysis (101,102) .
In the NC1 hexamer configuration, wherein the ␣3 NC1 domain interacts with its neighboring ␣4 and ␣5 NC1 domains, we found that both epitopes are cryptic (103, 104) , being inaccessible for antibody binding unless exposed by dissociation of the hexamer (Figure 10 ). This posed two other questions: "What is the three-dimensional localization of the epitopes?" "What is the basis of their crypticity?" For the answer, we determined the quaternary structure of the ␣3.␣4.␣5 hexamer (47) and then modeled its three-dimensional structure based on the x-ray structure of the homologous ␣1.␣1.␣2 hexamer (45). The findings revealed that the E A and E B are located near the triple-helical junction, and they are partially sequestered by interactions with the neighboring ␣5 and ␣4 NC1 domains (Figure 11 ).
Because the epitopes are hidden within the hexamer (103, 104) , it is presumed that an environmental factor, such as hydrocarbons (105) or tobacco smoke (106) , is required to expose the cryptic epitopes present in alveolar basement membrane to the immune system ( Figure 12 ). Indeed, in an experimental animal model, we showed that injection of monomers or dimers of ␣3 NC1 domain with exposed epitope induced anti-GBM disease (107, 108, 117) . Endogenous oxidants can also open this immunologically privileged site in the GBM (109, 110) . In contrast, the epitopes of the alloantibodies, produced in some renal transplant recipients with Alport syndrome, are fully accessible on the hexamer surface, reside on the NC1 domains of the ␣3 and ␣5 chains, and seem to be distinct from the E A and E B epitopes (95, 110) (Figure 12 ). This difference in structure between the epitopes for Alport alloantibodies and GP auto-antibodies may reflect crucial features of the mechanisms underlying the cause of autoimmune GP syndrome and, thus, warrant the crafting of questions for future explorations. Figure 10 . The identity and the cryptic nature of the E A epitope of the GP antigen. The immunodominant E A epitope was localized to a site, residues 17 to 31 (TAIPSCPEGTVPLYS), near the junction of the N-terminus of the NC1 domain and the triple-helical domain of the ␣3 chain of collagen IV. The epitope is cryptic, being inaccessible to GP antibodies until the hexamer is dissociated. The location of this E A epitope and that of the E B epitope are shown on the three-dimensional structure of the NC1 hexamer in Figure 11 .
Pathogenesis of Alport Syndrome and the Developmental Switch of the ␣3.␣4.␣5 Network
In 1927, Arthur Cecil Alport reported that deafness was a feature of a previously described familial nephropathy that caused uremia in males but spared females (111) . Splitting of the GBM, hematuria, interstitial nephritis, and progressive kidney failure explained the renal aspects of the disorder. With the discovery of a collagenous component in GBM in 1966, Spears postulated in 1972 that this collagen was defective in Alport syndrome (11) . The cause of Alport syndrome remained unknown until mutations were discovered in 1990 by Tryggvason and colleagues (79) in the COL4A5 gene encoding the ␣5 chain of collagen IV. Today, Ͼ300 different mutations in this gene have been identified. Subsequent studies have revealed that there are three genetic forms of Alport syndrome, all arising from mutations in the COL4A3, COL4A4, and COL4A5 genes (1, 16, 112, 113) . Full expression of Alport syndrome requires a mutation in the single COL4A5 allele carried by males with X-linked disease, or mutations in both alleles of COL4A3 and COL4A4 genes in subjects of either gender with the autosomal recessive form (17) . Heterozygous mutations in COL4A3 and COL4A4 genes underlie thin basement membrane nephropathy, causing mild abnormalities of renal function (14 -17) .
These mutations interfere with the assembly of the ␣3.␣4.␣5 network in the GBM. As a consequence, they arrest the normal developmental switch ( Figure 13A ) from the ␣1.␣1.␣2 network to the ␣3.␣4.␣5 network, causing the persistence ( Figure  13B ) of the former in the GBM (114) . Animal studies reveal that the ␣3.␣4.␣5 network is not essential for the early development of the glomerulus but is crucial for the long-term function of the filtration barrier later in life (115, 116) . We found that the embryonic ␣1.␣1.␣2 network (Figure 3 ) is more susceptible to proteolysis than the more heavily cross-linked ␣3.␣4.␣5 network (Figure 9) (92,114) . Thus, the absence of the latter network may lead to proteolysis, which may explain why the GBM of Alport patients thickens unevenly, splits, and ultimately deteriorates, leading to progressive renal failure.
Summary and Perspectives
The journey to unravel the molecular basis of GBM diseases has led to the discovery of the collagen IV family of six ␣-chains. Initial studies of diabetic nephropathy eventually resulted in the discovery of the ␣1 and ␣2 chains and their network organization. This network is a principal component of basement membranes underlying epithelia of all metazoa, as an ancient scaffold preserved Ͼ500 million years of evolution.
Our studies to unravel the molecular basis of GP syndrome directly led to the discovery of the ␣3 chain, which, in turn, led to the discovery of the ␣4, ␣5, and ␣6 chains and the defining of collagen IV as a family of six ␣-chains (␣1 to ␣6). The autoantibodies from patients with GP syndrome would prove to be the beacon for our discovery of the ␣3 and ␣4 chains. The Figure 11 . The atomic structure of the ␣3.␣4.␣5 NC1 hexamer. The atomic structure of the hexamer shows how two protomers interact end to end at their C-terminal NC1 domains to form a NC1 hexamer. The three NC1 monomers of each protomer interact to form a trimeric cap that, in turn, interacts with the trimeric cap from another protomer to form the hexamer. Each NC1 monomer has a novel three-dimensional fold of the polypeptide chain, characterized mainly by ␤-sheets, shown by the ribbon diagrams (left). The sites for the E A and E B epitopes are shown on the space-filling model of the hexamer (right). The atomic structure was modeled on the crystal structure of the homologous ␣1.␣1.␣2 NC1 hexamer. Figure 12 . GP autoantibodies and Alport alloantibodies target different epitopes of the ␣3.␣4.␣5(IV) NC1 hexamer. Anti-GBM antibodies derive from an antigen-specific T cell and B cell response (TϩB). The epitopes for the GP autoantibodies are inaccessible to anti-GBM antibodies unless there is a dissociation of the hexamer, which may be caused by oxidative stress. These epitopes reside on the ␣3(IV) NC1 domain and are partially sequestered by the adjacent ␣5(IV) NC1 and ␣4(IV) NC1 domains. In contrast, the epitopes for the Alport alloantibodies are accessible on the hexamer surface and reside on the ␣3(IV), ␣4(IV), and ␣5(IV) NC1 domains. Modified from reference 1, with permission. recognition of a "molecular commonality" between GP and Alport syndromes involving the GP antigen would prove to be a beacon for the discovery of the ␣5 and ␣6 chains.
Subsequently, we determined the network organization of the six ␣-chains in the glomerulus and discovered that the ␣3, ␣4, and ␣5 chains occur together in a single protomer (␣3.␣4.␣5 protomer), forming a novel ␣3.␣4.␣5 network (Figure 9) . This network provided a definitive explanation for the "molecular commonality" between GP and Alport syndromes. Moreover, the discovery of the ␣3.␣4.␣5 protomer and its network unified the findings of numerous investigators regarding the pathogenic mechanisms underlying several GBM diseases, as summarized in Figure 14 . The pathogenesis of GP syndrome and all three forms of Alport syndrome (X-linked and autosomal recessive and dominant) are linked to this protomer, as is the pathogenesis of thin basement membrane disease and antibody-mediated posttransplant nephritis in Alport syndrome. The very same protomer may be involved in the pathogenesis of diabetic nephropathy, because it is the principal component of normal GBM.
In a previous review, we proposed naming the ␣3.␣4.␣5 protomer the "Goodpasture protomer" (1). This name highlights the important role that the Goodpasture antibodies had in the discovery of this protomer and further relates the entire protomer to the pathogenesis of GP and Alport syndromes. The GP protomer now serves as a new beacon for crafting questions as the basis for discovery of fundamental mechanisms underlying autoimmunity, functions, and assembly of networks in health and disease. The answers will hopefully provide molecular insights that lead to new therapies for GP and Alport syndromes and diabetic nephropathy.
" Figure 14 . A schematic view of the ␣3.␣4.␣5 protomer (the GP protomer) and its role in renal diseases. Genetic mutations in the ␣5 chain leads to the X-linked form of Alport syndrome. Mutations in either the ␣3 or the ␣4 chain leads to the autosomal recessive and autosomal dominant forms of Alport syndrome and thin basement membrane disease. In Alport posttransplant anti-GBM nephritis, the alloantibodies are targeted to the NC1 domains of the ␣3 and ␣5 chains. In GP syndrome, the autoantibodies are targeted to the NC1 domain of the ␣3 chain. 
